Epidiolex maker files suit in U.S. to protect its patents

59 0

The maker of CBD prescription drug Epidiolex has filed a lawsuit in the USA alleging patent infringement.

GW Research Ltd, a subsidiary of Ireland-based Jazz Pharmaceuticals, claims that more than 15 drugmakers are violating its patents as they develop generic versions of Epidiolex, the only pharmaceutical containing CBD that is approved by the U.S. Food and Drug Administration (FDA).

Generic versions

Those competitors have submitted Abbreviated New Drug Applications (ANDAs) in order to “commercially market generic versions of GW’s cannabidiol oral solution drug product,” GW said in the lawsuit, noting some of the patents do not expire until September 2025, while the others are still in force until July 2027.

Read More